Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Li

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
EMBO Molecular Medicine|August 3, 2023
Viral anti-inflammatory serpin reduces immuno-coagulopathic pathology in SARS-CoV-2 mouse models of infectionLiqiang Zhang, Yize Henry Li, Karen Kibler, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2023
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation PneumonitisAndreas Rimner, Zachary R Moore, Stephanie Lobaugh, et al.
JTO Clinical and Research Reports|January 2, 2023
A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural MesotheliomaAndreas Rimner, Prasad S Adusumilli, Michael D Offin, et al.
PLOS Global Public Health|November 14, 2024
A consensus statement on dual purpose pathogen surveillance systems: The always on approachHelene-Mari van der Westhuizen, Srinidhi Soundararajan, Tamsin Berry, et al.
JAMA|November 28, 2018
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical TrialAleena Banerji, Marc A Riedl, Jonathan A Bernstein, et al.
Nature Communications|September 18, 2021
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IJohannes Brägelmann, Carina Lorenz, Sven Borchmann, et al.
Journal of the American College of Cardiology|July 16, 2025
The Global Syndemic of Modifiable Cardiovascular Risk Factors Projected From 2025 to 2050Bryan Chong, Jayanth Jayabaskaran, Silingga Metta Jauhari, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
The Journal of Allergy and Clinical Immunology|October 25, 2020
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trialBruce Zuraw, William R Lumry, Douglas T Johnston, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
EMBO Molecular Medicine|August 3, 2023
Viral anti-inflammatory serpin reduces immuno-coagulopathic pathology in SARS-CoV-2 mouse models of infectionLiqiang Zhang, Yize Henry Li, Karen Kibler, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2023
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation PneumonitisAndreas Rimner, Zachary R Moore, Stephanie Lobaugh, et al.
JTO Clinical and Research Reports|January 2, 2023
A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural MesotheliomaAndreas Rimner, Prasad S Adusumilli, Michael D Offin, et al.
PLOS Global Public Health|November 14, 2024
A consensus statement on dual purpose pathogen surveillance systems: The always on approachHelene-Mari van der Westhuizen, Srinidhi Soundararajan, Tamsin Berry, et al.
JAMA|November 28, 2018
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical TrialAleena Banerji, Marc A Riedl, Jonathan A Bernstein, et al.
Nature Communications|September 18, 2021
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IJohannes Brägelmann, Carina Lorenz, Sven Borchmann, et al.
Journal of the American College of Cardiology|July 16, 2025
The Global Syndemic of Modifiable Cardiovascular Risk Factors Projected From 2025 to 2050Bryan Chong, Jayanth Jayabaskaran, Silingga Metta Jauhari, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
The Journal of Allergy and Clinical Immunology|October 25, 2020
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trialBruce Zuraw, William R Lumry, Douglas T Johnston, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
Pageof 16